Pankreatische B-Zellen-Peptide: Kinetik und Konzentration von Proinsulin, Insulin und C-Peptid in Plasma und Urin, Probleme der Meßmethoden, klinische Aussage und Literaturübersicht

Gerbitz, Klaus-Dieter

doi:10.1515/cclm.1980.18.6.313

Cited by 6 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings raise the question of the nature of the molecular form(s) of proinsulin present in human serum. The cross-reactivity of intact proinsulin is less than 1% in our assay and yet the levels reported for this assay are similar to those reported using alternative methods (Heding, 1977;Gerbitz, 1980). Our results would suggest therefore that a major circulating form of 'proinsulin' in serum is a derivative cleaved either at a A or B chain side of C-peptide or a mixture of the two.…”

Section: Discussionsupporting

confidence: 84%

Proinsulin in Human Serum: Problems in Measurement and Interpretation

Gray

Siddle

Docherty

et al. 1984

Clinical Endocrinology

View full text Add to dashboard Cite

The immunoreactivity of an extracted pancreatic human proinsulin standard in an indirect immunoradiometric assay was found to be at least one hundred times higher than that of biosynthetic human proinsulin. Limited tryptic digestion of the biosynthetic proinsulin increased its immunoreactivity in the assay and this was attributed to the production of partially cleaved proinsulin molecules which still retained the C-peptide moeity. This inference was confirmed by the finding that pure samples of 65/A1 and 32/33 split proinsulins reacted in the assay very similarly to the pancreatic proinsulin standard. The implications of these results are that the immunoassays of proinsulin using antisera to C-peptide may recognise the intact proinsulin molecule very poorly, if at all, and that the 'proinsulin' measured by such assays of human serum may be largely if not entirely intermediates of proinsulin cleavage.

show abstract

Section: Discussionsupporting

confidence: 84%

Proinsulin in Human Serum: Problems in Measurement and Interpretation

Gray

Siddle

Docherty

et al. 1984

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Since 1980, this obstacle is overcome through the availability of biosynthetic human proinsulin and C-peptide. Examples for immunological studies are a very careful study with three assay systems using different antisera by Kuzuya et al, 1978, see [ 26 ], aiming at the detection and avoidance of pitfalls. Human proinsulin-specific antigenic determinants can be identified by monoclonal antibodies and allow hints towards the conformation of C-peptide (Madsen et al, 1984, see [ 27 ]).…”

Section: The Second Decade 1977–1986mentioning

confidence: 99%

“…The advances in methodology as well as the results of the large number of clinical studies between 1980 and 1986 are compiled in three reviews by Gerbitz [ 26 ], Polonsky and Rubenstein [ 27 ] as well as Faber and Binder [ 28 ]. Pitfalls and limitations in the determination of the secretion and hepatic extraction of insulin are discussed in [ 27 ].…”

Section: The Second Decade 1977–1986mentioning

confidence: 99%

History and Diagnostic Significance of C‐Peptide

Brandenburg

2008

Journal of Diabetes Research

View full text Add to dashboard Cite

Starting with the epoch-making discovery of proinsulin, C-peptide has played an important interdisciplinary role, both as part of the single-chain precursor molecule and as an individual entity. In the pioneering years, fundamental systematic experiments unravelled new biochemical mechanisms and chemical structures. After the first detection of C-peptide in human serum, it quickly became a most useful independent indicator of insulin biosynthesis and secretion, finding application in a rapidly growing number of clinical investigations. A prerequisite was the development of specific immuno assays for proinsulin and C-peptide. Further milestones were: the chemical synthesis of several C-peptides and the accomplishments in the synthesis of proinsulin; the detection of preproinsulin with its bearings on understanding protein biosynthesis; the pioneering role of insulin, proinsulin, C-peptide, and mini-C-peptides in the development of recombinant DNA technology; and the discovery of the enzymes for the endoproteolytic processing of proinsulin into insulin and C-peptide, completing the pathway of biosynthesis. Today, C-peptide continues to serve as a special diagnostic tool in Diabetology and related fields. Thus, its passive role is well established. Evidence for its active role in physiology and pathophysiology is more recent and is subject of the following contributions.

show abstract

“…Further, the HbA 1c fraction and mean blood glucose were obtained from the GHb%. Serum insulin was determined by insulin microplate ELISA technique using a commercial kit from Monobind Inc., CA, U.S.A (Gerbitz, 1979). Total cholesterol was determined (Lopes et al, 1977) in serum using a commercial kit from Biolab Diagnostics, India.…”

Section: Studies On Experimental Diabetic Ratsmentioning

confidence: 99%

Probable Mechanism of the Antihyperglycemic Effect of Standardized Extract from Momordica charantia in Streptozotocin Diabetic Rats

Naik¹,

Bumrela²,

Lagishetty³

et al. 2009

Journal of Complementary and Integrative Medicine

View full text Add to dashboard Cite

Recommended Citation: Naik, Suresh R.; Bumrela, Shrinivas B.; Lagishetty, Chakradhar V.; and Mandlik, Rahul V. (2009) "Probable Mechanism of the Antihyperglycemic Effect of Standardized Extract from AbstractThe herb Momordica charantia Linn has been used widely in India and other countries for the treatment of diabetes. In the present study reports the antihyperglycemic activity of standardised Momordica charantia extract (MCE) using in-vivo and in-vitro animal models along with the relevant biochemical and histopathological parameters. The antihyperglycemic activity of MCE was compared with that of glibenclamide, a known potent anti-diabetic drug. MCE treatment reduced blood glucose levels both in normal and streptozotocin (STZ)-induced diabetic rats, and also restored the glucose tolerance significantly in diabetic rats. MCE treatment enhanced glucose uptake process and increased liver glycogen. Furthermore, MCE treatment reduced the elevated serum lipids and glycosylated haemoglobin levels significantly and able to reverse histoarchitechture of β-islets of Langerhans in STZ-induced diabetic rats.The blood insulin levels were also restored significantly in STZ diabetic rats following MCE treatment. Present experimental findings with MCE suggest its antihyperglycemic activity and might be attributed to pancreatic (increased insulin secretion) and also extra pancreatic (through enzymes associated with glycogen synthesis and augmenting the utilization of glucose by peripheral tissues) mechanisms. Thus, MCE seems to be a clinically promising agent in the management of diabetes and/or hyperglycemic associated disorders.

show abstract

Pankreatische B-Zellen-Peptide: Kinetik und Konzentration von Proinsulin, Insulin und C-Peptid in Plasma und Urin, Probleme der Meßmethoden, klinische Aussage und Literaturübersicht

Cited by 6 publications

References 18 publications

Proinsulin in Human Serum: Problems in Measurement and Interpretation

Proinsulin in Human Serum: Problems in Measurement and Interpretation

History and Diagnostic Significance of C‐Peptide

Probable Mechanism of the Antihyperglycemic Effect of Standardized Extract from Momordica charantia in Streptozotocin Diabetic Rats

Contact Info

Product

Resources

About